Avid to Relist on NASDAQ BURLINGTON, Mass., Dec. 4, 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avid to Relist on NASDAQ

BURLINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Avid (OTC:AVID) today announced that it has received approval to list its common stock on The NASDAQ Stock Market, LLC effective with the open of trading on Monday, December 8, 2014. The Company will continue to trade under the symbol AVID.

"We are pleased that Avid stock will once again trade on the NASDAQ," said John Frederick, Executive Vice President, Chief Financial and Administrative Officer of Avid. "We believe this milestone offers current and future Avid shareholders an exciting opportunity to share in the success of our business through improved access to our common stock. We look forward to generating sustainable, profitable growth as we continue to execute on our plan to unlock the full potential of Avid."

Forward-Looking Statements

The information provided in this press release includes forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding our recently filed financial statements or other information included herein based upon or otherwise incorporating judgments or estimates, including statements herein relating to future performance such as our future adjusted EBITDA, earnings, bookings, free cash flow, payments for restatement-related expenses; our future strategy and business plans; and our anticipated timing for filing our future quarterly reports. These forward-looking statements are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Unknown risks and uncertainties include, but are not limited to the effect on our sales, operations and financial performance resulting from the identified material weaknesses in our internal control of financial reporting; the delisting of our stock from NASDAQ; the previously disclosed ongoing SEC and Department of Justice inquiries; pending litigation, including the previously disclosed class action and possibility of further legal proceedings adverse to our Company resulting from the restatement or related matters; the costs associated with the restatement; our liquidity; our ability to execute our strategic plan and meet customer needs; our ability to produce innovative products in response to changing market demand, particularly in the media industry; our ability to successfully accomplish our product development plans; competitive factors; history of losses; fluctuations in our revenue, based on, among other things, our performance in particular geographies or markets, fluctuations in foreign currency exchange rates and seasonal factors; adverse changes in economic conditions; and variances in our backlog and the realization thereof. Moreover, the business may be adversely affected by future legislative, regulatory or tax changes as well as other economic, business and/or competitive factors. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described in our filings with the SEC. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

About Avid

Through Avid Everywhere ™, Avid delivers the industry's most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption for the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, music recordings, and television shows, to live concerts and news broadcasts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, and Sibelius®. For more information about Avid solutions and services, visit www.avid.com , connect with Avid on Facebook , Instagram , Twitter , YouTube , LinkedIn ; or subscribe to Avid Blogs .

© 2014 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Media Composer, Pro Tools, Interplay, ISIS, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. The Interplay name is used with the permission of the Interplay Entertainment Corp. which bears no responsibility for Avid products. All other trademarks are the property of their respective owners.

Media Contact Lisa Kilborn Avid 978.640.3230 Investor Contact Tom Fitzsimmons Avid 978.640.3346

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading